Taking into account the fact that there is a close relationship between obesity, PPAT, and prostate cancer, a new field is opened for research aimed at explaining GIP as well as GLP-1 agonist and what effect the novel agents used in the treatment of obesity have on the biology of prostate cancer. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.